DIRECTIONS IN LUNG CANCER THERAPY FOR OLDER PATIENTS

FACULTY

Alan B. Sandler, MD
Associate Professor of Medicine
Medical Director, Thoracic Oncology
Director, Vanderbilt-Ingram Cancer Center Affiliate Network
Vanderbilt University Medical Center
Division of Hematology/Oncology
Nashville, Tennessee

MODERATOR

Roy S. Herbst, MD, PhD
Professor of Medicine
Chief, Section of Thoracic Medical Oncology Co–Chairman, Phase I Working Group
Department of Thoracic/Head and Neck Medical Oncology Department of Cancer Biology The University of Texas MD Anderson Cancer Center
Houston, Texas

PURPOSE STATEMENT

Directions in Lung Cancer Therapy for Older Patients will discuss treatment regimens and management strategies for elderly patients with lung cancer, including current recommendations and clinical trial data that may affect the care of these patients.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Explain the variations in physiology in the elderly and comorbid conditions that may affect lung cancer therapy.
• Describe current recommendations for treating elderly patients with lung cancer.
• Discuss the results of trials investigating management strategies for the treatment of lung cancer in the elderly and how this information may be used to optimize the care of these patients.
  

TARGET AUDIENCE

Directions in Lung Cancer Therapy for Older Patients is intended for medical, surgical, and radiation oncologists and oncology nurses, as well as other healthcare professionals interested in the management of patients with lung cancer.

ACCREDITATION INFORMATION

Expiration date: September 24, 2008

Physicians: Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Med-IQ designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurses (CBRN): Med-IQ is a provider approved by the California Board of Registered Nursing, Provider Number CEP #14745, for 1.0 Contact Hours.

Pharmacists:
1 contact hours (0.100 CEUs) of credit for pharmacists. This activity co-sponsored by Medical Education Collaborative, Inc. (MEC) and Med-IQ. MEC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
ACPE # 815-999-07-059-H01. The program is designed for all pharmacists.

Other Credit Information
Nurse Practitioners: Med-IQ is accredited by ACCME to provide continuing medical education for physicians, and will provide nurse practitioners who successfully complete the activity with a Statement of Participation indicating that the activity was designated for 1 AMA PRA Category 1 Credit^TM.

Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit^TM for the PRA from organizations accredited by ACCME.

Disclosure Policy
It is the policy of Med-IQ that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during presentation(s). Individuals who refuse to disclose will be disqualified from all aspects associated with this CME activity. Med-IQ has policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Med-IQ Disclosure
Reshma Carter has disclosed that her spouse is an employee of Novartis Pharmaceuticals.

All other employees of Med-IQ have no financial relationships to disclose.

MEC Disclosure
The employees of Medical Education Collaborative have no financial relationships to disclose.

Acknowledgement of Commercial Support
This educational series is supported by an educational grant from sanofi-aventis U.S.